Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TumoCure
- Development stage
- Phase 1
- Lead developer
- IntraGel Therapeutics
- Modality
- Small Molecules, Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intratumoral
01
Overview
**TumoCure** is an investigational, biodegradable polymer-based sustained-release gel formulation containing cisplatin at 100 mg/mL. Developed by IntraGel Therapeutics for local intratumoral chemotherapy, it is designed to provide prolonged tumor-local cisplatin exposure while reducing systemic platinum exposure and associated toxicity relative to intravenous cisplatin. It is being evaluated as a single intratumoral injection for progressive or radio-resistant head and neck tumors, with preclinical evidence supporting use alone and in combination with radiotherapy.
- Other names
- cisplatin-SRGelSRGel-Cisplatin
02
Targets
DNA
Beyond the preview
Go deeper on TumoCure.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TumoCure.